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Background: Antimalarials quinacrine (Qc) and chloroquine (Cq) intercalate DNA, potentiate the activity of other
drugs and have lysosomotropic, anti-inflammatory and antiviral activities that could increase the effect of the
3′-azido-3′-deoxythymidine (AZT) antiretroviral agent. The aim of the current study was to evaluate if Qc and Cq
could improve the in vitro effect of the antiretroviral AZT agent.
Findings: Inhibition of viral replication in human immunodeficiency virus (HIV)SF33-infected peripheral blood
mononuclear cells treated with Qc or Cq, alone or combined with a low dose of AZT was measured. Viral
replication increased with Qc and decreased with high doses of Cq. The increase of replication caused by Qc was
reversed by AZT. Neither Qc nor Cq significantly changed the antiviral activity of AZT.
Conclusion: Cq does not potentiate the effect of AZT, but it is effective by itself at high doses. The rise of HIV
replication by Qc could be deleterious in HIV endemic regions, where it is used as antimalarial. The mechanisms
associated to this phenomenon must be identified.
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Introduction
Human immunodeficiency virus (HIV)/acquired immuno-
deficiency syndrome morbidity and mortality have de-
creased with the use of antiretroviral therapy (ART).
However, therapy adherence is frequently diminished by
ART toxicity [1], which might in turn lead to emergence
of resistant HIV strains [2].
Chloroquine (Cq) and quinacrine (Qc) have been widely
used for decades as antimalarials, both have a well charac-
terized biosafety and pharmacological profile [3]. The ac-
cumulation of Cq in breast milk of HIV infected women
[4], and a decreased vertical transmission of HIV induced
by this drug have been observed in malaria endemic coun-
tries [5]. Cq and Qc also have strong DNA intercalating* Correspondence: mariluci_aguirre@hotmail.com
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unless otherwise stated.properties [6], as well as special tropism for lysosomes [7],
and concentrate for long periods in lymphoid tissue [8,9].
Due to the afore mentioned pharmacological properties,
these drugs could be used as inhibitors of HIV replication
[10,11]. Both drugs have also been linked to inhibition of:
immune activation [12]; intracellular production of inter-
feron [13]; nuclear factor-kappa B activation [14]; calcium
signals in T cells [15]; and RNA polymerase activity [16].
Qc intercalation in viral DNA or RNA inhibits DNA mu-
tations [17]. Additionally, Cq potentiates the activity of
some antineoplastic drugs [18]. In this study, we evaluated
the in vitro effect of Qc and Cq on HIV replication, ad-
ministered alone or combined with low concentrations
of the ART agent, 3′-azido-3′-deoxythymidine (AZT),
in order to search for a possible additive effect of the
antimalarial drug-AZT combinations.
Methods
Peripheral blood mononuclear cells (PBMCs) proveni-
ent from different human voluntary healthy donors were
used instead of CD4+ T cells, for better availability in
our laboratory. The protocol was approved by theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Diseases. PBMCs were purified by density gradient cen-
trifugation and cultured at 37°C, 5% CO2 and 85% H2O,
in RPMI-1640 medium, supplemented with fetal bovine
serum (BioWhittaker, Anaheim CA), antibiotics Penicillin-
Streptomicyn (BioWhittaker, Anaheim CA), L-Glutamine
(BioWhittaker, Anaheim CA) and human IL-2 (20 U/ml,
Roche, USA), as previously described [19]. In order to de-
termine the cytotoxicity effect, the viability of uninfected
PBMCs, treated at the same drug concentrations, used in
the drug assay, was measured using trypan blue exclusion
staining (0.04%, Cambrex, USA). The percentage of viable
cells was determined dividing the number of alive cells ×
100/total cells. HIVSF33 virus isolated and donated by Levy
et al. [20], was tittered on phytohemagglutinin-stimulated
PBMCs for determining the tissue culture infectious dose
50 (TCID50), as described by McDougal [21]. Viral stocks
were then stored frozen at −80°C until their use. PMBCs
were infected with HIVSF33 (500 TCID50/1×10
6 cells) by
2 h at 37°C, and extensively washed to remove the virus,
and cultured during 4 days in the presence of the follow-
ing treatments: Phosphate Buffered Saline (PBS, 15 mM
as control); AZT (0.008 μM, ID50); Qc (0.4-2 μM); Cq
(5–20 μM); or the mixtures Qc (0.4-2 μM) + AZT
(0.008 μM); Cq (5–20 μM) + AZT (0.008 μM). On the
fourth day of culture, the viral replication, measured as
level of HIV-1 p24 antigen, was tested by Enzyme-
Linked ImmunoSorbent Assay (ELISA, Beckman Coulter,
Fullterton, CA). Absorbance (450 nm) was measured with
the CODA EIA automated Analyzer (Bio-Rad, Hercules,
CA) and concentration was calculated with CODA soft-
ware. All assays were run in triplicate on three different
days (n = 9), using the same HIVSF33 virus stock. TheTable 1 Viability of peripheral blood mononuclear cells treate
3′-azido-3′-deoxythymidinea
Drug Dose (μM) Treatment
Cellsb (mean ± SD) %
PBS (Control) - 247 ± 61 8
3′-azido-3′-deoxythymidine, AZT 0.008 238 ± 70 8
Quinacrine, Qc 0.4 213 ± 66 8
1 186 ± 96 8
5 139 ± 69 7
Chloroquine, Cq 5 216 ± 64 8
10 184 ± 67 8
20 106 ± 36 6
aPurified uninfected PBMCs were treated with PBS, Qc, Cq or AZT and incubated du
staining. Dead (blue) and alive (unstained) cells were counted. The percentage of v
bMean value (+/− standard deviation) of viable cells from three independent assays
cStudent’s t-test between treatment alone and combined with AZT at the same con
dPost-hoc Tukey’s test of concentration compared with control, p = 0.0363.
ePost-hoc Tukey’s test of concentration compared with control, p = 0.0033.
ns = not significant.percentage of inhibition of replication was determined by
calculating percent reduction HIV p24 antigen in wells
containing the drugs and were compared with control
(PBS) using the formula: HIV p24 antigen in PBS - HIV
p24 antigen drug treatment × 100/HIV p24 antigen in
PBS. Statistical analysis included Student’s t-test to com-
pare cell viability between drug treatment alone or com-
bined and one-way analysis of variance (ANOVA) test
followed by the Tukey’s post-hoc test to compare inhib-
ition of HIV replication between AZT and Cq or Qc treat-
ments using the GraphPad Prism 6 software. Differences
were considered significant when p-value was < 0.05.
Results
Table 1 shows the cell viability in cultures treated with
AZT, Qc or Cq. It can be seen that the tested dose of
AZT (0.008 μM) did not reduce cell viability compared
to PBS control PBMCs. Both Qc and Cq produced dose-
related decreases in cell viability, with significant reductions
in percentage occurring at the highest concentrations of
Qc (5 μM, p = 0.038) and Cq (20 μM, p = 0.004), when
compared with PBS control. Addition of AZT to Qc or Cq
did not cause any further increase in cytotoxicity.
The low dose of AZT used in this report was selected
to yield modest inhibition of HIVSF33 replication so that
effects of coadministration of Qc or Cq could be observed.
Treatment with 0.008 μM AZT alone significantly inhib-
ited HIVSF33 replication by nearly 50% (t-test, p = 0.0061)
compared to PBS. Qc (0.4-2 μM) administered alone
caused increases in HIV replication that appeared to be
inversely related to dose of the antimalarial drug
(Figure 1A) (p = <0.0001). This enhancement of viral
replication by Qc alone was reversed by co-administrationd with PBS, quinacrine, chloroquine or
Treatment combined with AZT (0.008 μM)
of viability Cellsb (mean ± SD) % of viability (p)c
7 ± 7 - - -
5 ± 6 - - -
8 ± 8 198 ± 63 90 ± 5 ns
3 ± 14 208 ± 60 86 ± 7 ns
1 ± 17d 126 ± 59 71 ± 12 ns
8 ± 8 210 ± 83 89 ± 5 ns
6 ± 10 179 ± 60 84 ± 7 ns
8 ± 17e 99 ± 47 63 ± 10 ns
ring 4 days. Cell viability was determined by using trypan blue exclusion
iable cells was determined dividing the number of alive cells × 100/total cells.
by triplicate (n = 9).
centration.
Figure 1 In vitro inhibition of HIV replication by different drug treatments: Quinacrine (A) and Chloroquine (B). HIV p24 antigen (ng/ml)
was measured in supernatants of cultures of peripheral blood mononuclear cells, infected with the HIVSF33 strain. Cells were treated during 4 days
with 3′-azido-3′-deoxythymidine (AZT) (control), Quinacrine (Qc), Chloroquine (Cq) or the mixtures Qc-AZT or Cq-AZT. Each bar represents the
mean +/− standard error of three independent assays by triplicate (n = 9). One-way ANOVA, followed by Tukey’s post-hoc test, was used to
compare: A, Control (AZT) and Qc or AZT- Qc; and B, Control (AZT) and Cq or AZT-Cq. Statistical significant p-values are shown in the figure.
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produced by Qc plus AZT being similar to that provided
by AZT alone (Figure 1A). In contrast, administration of
Cq alone at low dose (5 μM) yielded modest, but signifi-
cant inhibition of viral replication of 10%, while higher
dose of Cq (20 μM) inhibited HIV replication around
80% (Figure 1B) (p = 0.0463). Inhibition of replication by
AZT-Cq combination was higher to that obtained with
AZT alone (p = 0.0035), but was similar to that obtained
with Cq alone (10 μM) (Figure 1B).
Discussion
The aim of the current study, was to evaluate if Qc and
Cq could improve the in vitro effect of the antiretroviralAZT agent. Qc and Cq were evaluated at different con-
centrations, administered alone or combined with AZT.
AZT is one of the drugs used in the ART in develop-
ing countries of low incomes, where many people do not
have access to the expensive new antiretroviral agents
[22]. Cq, a widely used drug for the treatment of
malaria, has shown antiviral effects [10], lysosomotropic
activity [7] and a preferential affinity for lymphoid tis-
sues [8,9], useful properties against HIV. In turn, the
anti-HIV effect of Qc, other DNA-intercalating agent
[6], has not been evaluated.
Results showed that the treatment of HIV-infected
PBMCs with Qc alone, increased HIV replication. This
result had not been reported before, but some studies
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possible regulation of the HIV entry in the cells and
anti-HIV microRNAs [23,24]. When the combination Qc-
AZT was evaluated, the HIV inhibition was similar to that
obtained with AZT alone, which could be explained by the
anti-HIV effect of AZT.
Previous reports have shown that Cq inhibits viral rep-
lication [25]. In the present study, the same effect was
observed at high doses (10–20 μM). When these doses
were combined with AZT, the inhibition was similar
than that obtained with Cq alone, and higher than AZT.
This result suggests that the HIV inhibition is related to
the intrinsic effect of Cq. The inhibition of HIV replica-
tion with a low dose of Cq-AZT (5 and 0.008 μM,
respectively) was not significantly different from that
observed by administration of AZT alone. Considering
that both effects are independent, the combination
AZT-Cq does not improve the anti-HIV effect.
Conclusion
Given our results, the use of Qc as antimalarial agent in
untreated HIV patients should be carefully observed, due
to the possible increase of HIV viral load. We can con-
clude that, neither Cq or Qc improve the efficacy of AZT.
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